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Rationale: There was an increased number of malignancies in infliximab-treated (5.7%) over
placebo-treated (1.3%) patients in a 44-week, phase 2 clinical study of 234 patients with
moderate-to-severe chronic obstructive pulmonary disease (COPD).
Objectives: To collect malignancy and mortality data from completed clinical studies of inflix-
imab in COPD treatment.
Methods: The multicenter, observational Remicade Safety Under Long-Term Study in COPD
(RESULTS COPD) collected malignancy and mortality data every six months for five years from
patients who received 1 study-agent dose in a phase 2 study. Co-primary endpoints were the
number of patients with malignancy and the number of deaths. Secondary endpoints included
the number of patients with a malignancy according to malignancy type.
Results: There was a gap period between the end of the phase 2 study and the initiation of
RESULTS COPD, during which six malignancies and 14 deaths were reported spontaneously
for the 107 (45.7%) of 234 patients with long-term safety information. Twenty-eight patients
(overall 12.0%; placebo 10.4%, infliximab 12.7%) reported malignancies, including 12 patients
during RESULTS COPD. Twenty-six patients (overall 11.1%; placebo 9.1%, infliximab 12.1%)
died, including nine during RESULTS COPD. Lung cancer was the most common malignancy type
(placebo n Z 2; infliximab n Z 10).
Conclusions: The greater proportion of malignancies observed with infliximab versus placebo
in a phase 2 study diminished over the long-term follow-up. Due to the observational nature,2 559 7313; fax: þ1 402 559 4878.
du (S.I. Rennard).
2 Published by Elsevier Ltd.
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Infliximab long-term safety in COPD 425limited patient participation, potential reporting bias from the interim spontaneous reporting
period, and unblinding of all patients, more definitive conclusions cannot be drawn.
Trial Registration Number: NCT00056264.
ª 2012 Published by Elsevier Ltd.Introduction
Chronic obstructive pulmonary disease (COPD) is a generally
progressive, not fully reversible disease that limits expira-
tory airflow. It results from inflammation and tissue damage
and leads to tissue alterations including emphysema and/or
bronchitis and fibrosis.1,2 Symptoms of COPD include cough,
sputum production, and dyspnea, which can be exacerbated
with physical exertion. In addition, extrapulmonary mani-
festations are common.3,4 Smoking is a causative factor of
COPD5 and increases the risk for several types of cancer.6
The leading causes of death among patients with smoking-
related COPD are lung cancer,7e9 followed by pulmonary-
related and cardiovascular causes.10 Additional research
suggests that the disease pathology in COPD and lung cancer
is due to similar underlying cellular and molecular mecha-
nisms.11,12 In support of this, patients with COPD have an
increased risk for the development of pulmonary malignan-
cies independent of smoking status.13e20
Preclinical studies have suggested that tumor necrosis
factor alpha (TNFa) may play a pathogenic role in
COPD.21e23 Infliximab (Janssen Biotech, Inc., Horsham, PA,
United States [USA]) is a human-murine chimericmonoclonal
antibody that neutralizes TNFa. In a phase 2, multicenter,
double-blind, placebo-controlled study conducted in the US,
234 patients with moderate-to-severe COPD were random-
ized to receive intravenous infusions of either placebo,
infliximab 3 mg/kg, or infliximab 5 mg/kg at weeks 0, 2, 6,
12, 18, and 24. Patients treated with infliximab showed no
evidence of treatment benefit, as measured by the analysis
of the primary endpoint (change from baseline fromweek 24
in the Chronic Respiratory Questionnaire [CRQ] total score),
when compared with those who received placebo.24 While
infliximab was generally well tolerated through week 44,
malignancies were reported at a higher frequency in the
combined infliximab group (nZ 9; 5.7%) than in the placebo
group (n Z 1; 1.3%). In the two published investigator-
initiated studies, no malignancies were reported.25,26
Because the actual malignancy risk is difficult to assess in
clinical trials, the long-term, observational Remicade Safety
Under Long-Term Study in COPD (RESULTS COPD) was con-
ducted to collect additional information on malignancy and
death risk in patients who participated in clinical studies of
infliximab for the treatment of COPD.
Methods
Patients
All consenting patients who received at least one dose of
study-agent in any of the three aforementioned interven-
tional clinical studies of infliximab in COPD were eligible to
participate in RESULTS COPD. It should be noted that of the
43 sites that participated in these three clinical studies, 19sites (17 in the US and two in The Netherlands which con-
ducted the investigator-initiated studies) opted not to
participate in the RESULTS COPD study. All participating
patients provided written informed consent before the
collection of any long-term safety follow-up information.
This study was conducted in accordance with the principles
of the Declaration of Helsinki and all other applicable
national and local laws and regulations.
Study design
This was a multicenter, long-term, observational study of
the safety of infliximab treatment in patients with
moderate-to-severe COPD. All consenting patients were to
begin participation in RESULTS COPD for a total duration of
five years of safety follow-up as soon as possible after their
last safety visit in the interventional infliximab study.
Because the majority of patients with COPD are smokers5
and to investigate the increased risk in this patient pop-
ulation for the development of lung and/or laryngeal cancer,
RESULTS COPD opted to include high resolution computed
tomography (CT) chest scans (spiral preferred) at study
entry and the final visit. Additionally, chest X-ray (posterior
and lateral), medical history review, and physical exami-
nation (including ear, nose, and throat) were performed at
study entry and the final visit. Data were collected from all
patients (or next of kin) at death (date and cause) and/or
malignancy (date of diagnosis and malignancy type) at six-
month intervals through direct contact, medical record
review, or contact with the patients’ primary care physician
or oncologist. Any death and/or malignancy events that
occurred between the end of an interventional infliximab
study and the commencement of RESULTS COPD were
collected via spontaneous reporting. Information on other
adverse events was not collected.
The co-primary endpoints of RESULTS COPD were the
number of patients with a malignancy and the number of
patients who died throughout the course of the follow-up.
Secondary endpoints were the number of patients with
malignancy identified by malignancy type (ie, lymphoma,
head and neck cancers, lung cancer, and other), the time to
death, and the time to the onset of malignancy.
Statistical analyses
The two analyzed populations in this study were all treated
patients from the interventional infliximab study
(NCT00056264) and all treated patients with long-term
safety follow-up information (ie, patients with data spon-
taneously reported to the sponsor during the gap period in
addition to patients who had consented to participate in
RESULTS COPD). Patients were analyzed according to the
treatment received during the interventional study (ie,
placebo, infliximab 3 mg/kg, and infliximab 5 mg/kg). Data
426 S.I. Rennard et al.from the following three periods were pooled for analysis:
primary study (NCT00056264) through week 44, gap period,
and RESULTS COPD through the final visit. Statistical
comparisons were made between the placebo and each
infliximab treatment group as well as between the placebo
and combined infliximab treatment group. No formal
hypothesis testing was planned; however, comparative
statistics such as hazard ratios and confidence intervals
(CIs) were computed. Primary endpoint analysis was con-
ducted on all treated patients in the primary study. Hazard
ratios for malignancies and deaths based on the Cox
proportional hazards model (using treatment as the only
covariate) and 95% confidence intervals were computed.
KaplaneMeier estimates of the cumulative incidence of
deaths and malignancies were calculated.
Results
Patient data availability
Both sites of the two investigator-initiated studies declined
to participate in RESULTS COPD. Of the 41 US sites that
participated in the phase 2 clinical study of infliximab, 24
sites opted to participate in RESULTS COPD. Long-term
safety follow-up data were available for 107 (45.7%) of 234
patients who had participated in the phase 2 interventional
study (Table 1). There was a gap period between the end of
the phase 2 interventional study (December 2004) and the
commencement of RESULTS COPD (April 2006). Ninety-
three (86.9%) of these 107 patients were alive at the start
of RESULTS COPD, and 14 (13.1%) had died during the gap
period. Of the remaining 127 patients who did not partici-
pate in RESULTS COPD, 9 were lost to follow-up, 33 did not
consent (or withdrew consent), and 85 were treated at
study sites that declined to participate.
Baseline demographics and disease characteristics
The number of patients per group was well balanced in the
107 patients who consented to participate in RESULTS COPD
(placebo n Z 35, infliximab 3 mg/kg n Z 35, infliximab
5 mg/kg n Z 37; Table 2). There were more males (57.0%)Table 1 Patient status at study entry into RESULTSa COPD; trea
Placebo I
3
Patients treated in phase 2 study 77 7
Treated patients with long-term safety
follow-up information
35 (45.5) 3
Status at RESULTSa COPD study entry
Alive 33 (42.9) 3
Lost to follow-up 5 (6.5) 3
Withdrew consent 12 (15.6) 9
Died 2 (2.6) 4
Patients not participating in
RESULTSa COPD
25 (32.5) 3
Data presented as n n (%).
a Remicade Safety Under Long-Term Study in chronic obstructive puthan females (43.0%). The majority (96.3%) of patients
were white. The median age at baseline was similar across
treatment groups (65e67 years). Patient baseline demo-
graphics were generally comparable between RESULTS
COPD and the phase 2 interventional study. Almost half
(48.6%) of the patients in RESULTS COPD had both chronic
emphysema and chronic bronchitis at baseline of the
primary study, whereas many patients (40.6%) in the phase
2 interventional study only had chronic emphysema at
baseline. Current smokers at study entry were a smaller
percentage of patients in RESULTS COPD than in the phase 2
interventional study.
Medication use
During the interventional study, the average duration of
study-agent exposure in the combined infliximab treatment
group was 18.6 weeks, and the median cumulative dose of
infliximab received was 18.0mg/kg in the infliximab 3mg/kg
group and 30.0 mg/kg in the infliximab 5 mg/kg group. One
patient who was in the infliximab 5 mg/kg group reported
a malignancy (pulmonary carcinoma) during the gap period
and had received infliximab within six months of malignancy
onset; this patient also died during the gap period. Only one
patient, who was in the placebo group during the interven-
tional study,was receiving commercial infliximab at RESULTS
COPD study entry for another indication, although two other
patients (one from the placebo group and one from the
infliximab 3 mg/kg group of the interventional study)
received commercial infliximab for other indications through
the end of RESULTS COPD. None of these three patients had
amalignancy or died during RESULTS COPD. No patients were
receiving any commercial anti-TNFa therapy other than
infliximab during RESULTS COPD.
Disposition
Of the 93 patients alive at RESULTS COPD study entry, 66
(71.0%) completed the study (Table 3). The remaining 27
(29.0%) patients were either lost to follow-up (15.1%),
withdrew consent (5.4%), or died during the follow-up
(8.6%).ted patients in the primary study.
nfliximab Total
mg/kg 5 mg/kg Combined
7 80 157 234
5 (45.5) 37 (46.3) 72 (45.9) 107 (45.7)
1 (40.3) 29 (36.3) 60 (38.2) 93 (39.7)
(3.9) 1 (1.3) 4 (2.5) 9 (3.8)
(11.7) 12 (15.0) 21 (13.4) 33 (14.1)
(5.2) 8 (10.0) 12 (7.6) 14 (6.0)
0 (39.0) 30 (37.5) 60 (38.2) 85 (36.3)
lmonary disease (COPD).
Table 2 Baseline demographics and disease characteristics.
Phase 2 interventional study RESULTSa COPD
Placebo Infliximab Placebo Infliximab
3 mg/kg 5 mg/kg 3 mg/kg 5 mg/kg
Patients randomized in phase 2 interventional study 77 78 79 e e e
Patients treated in phase 2 interventional study 77 77 80 e e e
Patients in RESULTSa COPD with long-term safety
follow-up information who were treated in
phase 2 interventional study
e e e 35 35 37
Male 46 (59.7) 48 (61.5) 44 (55.7) 18 (51.4) 23 (65.7) 20 (54.1)
White 71 (92.2) 77 (98.7) 75 (94.9) 32 (91.4) 35 (100.0) 36 (97.3)
Black 5 (6.5) 1 (1.3) 4 (5.10) 3 (8.6) 0 1 (2.7)
Other 1 (1.3) 0 0 0 0 0
Ages (years) 66.0 65.0 66.0 67.0 68.0 65.0
Weight (kg) 80.9 76.9 74.0 77.3 76.4 77.2
COPDb type
Chronic bronchitis 25 (32.5) 14 (17.9) 15 (19.0) 9 (25.7) 1 (2.9) 7 (18.9)
Emphysema 30 (39.0) 32 (41.0) 33 (41.8) 13 (37.1) 12 (34.3) 13 (35.1)
Both 22 (28.6) 32 (41.0) 31 (39.2) 13 (37.1) 22 (62.9) 17 (45.9)
Smoking status at study entry
Current smoker 33 (42.9) 35 (45.5) 35 (43.8) 11 (33.3) 6 (19.4) 7 (24.1)
Former smoker 44 (57.1) 42 (54.5) 45 (56.3) e e e
Median total pack- years 55 50 53 e e e
Median number cigarettes smoked daily e e e 20.0 12.5 25.0
Data presented as n, n (%), or median. 1 pack-year Z 20 cigarettes smoked every day for 1 year or the equivalent.
a Remicade Safety Under Long-Term Study in chronic obstructive pulmonary disease (COPD).
b Chronic obstructive pulmonary disease.
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Of the 234 patients treated in the phase 2 interventional
infliximab study, there were 28 (12.0%) reports of malig-
nancy. Of these patients, 10 reported a malignancy during
the interventional study, 6 during the gap period, and 12
during RESULTS COPD. Although a greater percentage of
patients reported a malignancy with infliximab than placebo
during the phase 2 interventional study (5.7% vs. 1.3%), this
imbalance appeared to diminish over time, including the gap
period (1.9% vs. 3.9%) and RESULTS COPD (5.1% vs. 5.2%),
respectively. The cumulative incidence of reported malig-
nancies was similar between the placebo (nZ 8 [10.4%]) andTable 3 Patient disposition in RESULTSa COPD.
Placebo Inflixima
3 mg/kg
Treated patients who
consented to participate
in RESULTSa COPD
33 31
Completed study 24 (72.7) 21 (67.7
Terminated study 9 (27.3) 10 (32.3
Lost to follow-up 4 (12.1) 4 (12.9)
Withdrew consent 1 (3.0) 3 (9.7)
Died 4 (12.1) 3 (9.7)
Data presented as n or n (%).
a Remicade Safety Under Long-Term Study in chronic obstructive puthe infliximab 5 mg/kg (n Z 8 [10.0%]) groups and was
highest in the infliximab 3 mg/kg group (nZ 12 [15.6%]).
The incidence of all malignancies per 100 patient-years
of follow-up was 3.89 (95% CI: 1.68, 7.66) in the placebo
group compared with 5.91 (95% CI: 3.05, 10.32) in the
infliximab 3 mg/kg group and 4.18 (95% CI: 1.80, 8.23) in the
infliximab 5 mg/kg group. Baseline age, sex, race, and
COPD type did not appear to influence the proportion of
patients who developed malignancies (data not shown).
However, regardless of active or placebo treatment,
patients who smoked 50 pack-years developed almost
twice as many malignancies as patients who smoked <50
pack-years (14.9% vs. 8.0%).b Total
5 mg/kg Combined
29 60 93
) 21 (72.4) 42 (70.0) 66 (71.0)
) 8 (27.6) 18 (30.0) 27 (29.0)
6 (20.7) 10 (16.7) 14 (15.1)
1 (3.4) 4 (6.7) 5 (5.4)
1 (3.4) 4 (6.7) 8 (8.6)
lmonary disease (COPD).
Figure 1 KaplaneMeier estimates of the cumulative inci-
dence of malignancy in 234 treated patients in the phase 2
interventional study.
428 S.I. Rennard et al.Malignancies common in smokers (ie, lung cancer and
head and neck cancers) tended to occur more often in
patients treated with infliximab, whereas other malignan-
cies tended to occur more often with placebo. However,
due to the small number of cases, all confidence intervals
of incidences overlapped. Lung cancer was the most
common malignancy (nZ 12; Supplementary Table E1) and
occurred more often in the infliximab groups. For the entire
period, two lung cancers were reported among patients
treated with placebo, five among patients treated with
infliximab 3 mg/kg, and five among patients treated with
infliximab 5 mg/kg. Three lung cancers were reported
during the 44-week randomized trial: zero, two, and one, in
the placebo, infliximab 3 mg/kg, and infliximab 5 mg/kgTable 4 Malignancy and death.
Placebo In
3
Treated patients in phase 2 study 77 77
Malignancies
Patients with 1 malignancies 8 (10.4) 12
Phase 2 study 1 (1.3) 5
Gap period 3 (3.9) 0
RESULTSa COPD 4 (5.2) 7
Hazard ratio (95% CIb)c e 1.
Incidence per 100 patient-years
(95% CI)d
3.89 (1.68, 7.66) 5.
Deaths
Patients who died 7 (9.1) 7
Phase 2 study 1 (1.3) 0
Gap period 2 (2.6) 4
RESULTSa COPD 4 (5.2) 3
Hazard ratio (95% CIb)c e 1.
Data presented as n or n (%) unless specified otherwise.
a Remicade Safety Under Long-Term Study in chronic obstructive pu
b Confidence interval.
c Based on the Cox proportional hazards model.
d Confidence intervals (CI) are based on an exact method.groups, respectively. Four were reported in the gap period
in only the infliximab 5 mg/kg group. In the RESULTS follow-
up trial, two, three, and one patients reported lung cancer
in the placebo, infliximab 3 mg/kg, and infliximab 5 mg/kg
groups, respectively.
For the 234 patients treated in the phase 2 interven-
tional study, the hazard ratio for time to malignancy for
infliximab versus placebo was 1.64 (95% CI: 0.67, 4.07) for
the infliximab 3 mg/kg group and 1.11 (95% CI: 0.42, 2.96)
for the infliximab 5 mg/kg group. Overall, the cumulative
incidence of malignancy over time was similar across all
treatment groups, and no apparent differences were
observed over time in the placebo and combined infliximab
groups (Fig. 1) with the exception of the end of the study
where more malignancies were observed in the infliximab
3 mg/kg group. The apparent disproportionate number of
malignancies identified toward the end of the five-year
follow-up period could be due to the protocol-
recommended chest CT at the last visit leading to the
detection of lung nodules, some of which were not defini-
tively diagnosed by the end of the study. To be conserva-
tive, nodules that were suspicious for malignancy, but
without biopsy confirmation, were categorized as malig-
nancies regardless, since there would be no additional
follow-up after the study was completed. The numbers
of these events were two for placebo, one for infliximab
3 mg/kg, and zero for infliximab 5 mg/kg.Death
Of the 234 patients treated in the phase 2 interventional
study, 26 (11.1%) patients died: 3 during the 44-week
randomized trial, 14 during the gap period, and 9 during
RESULTS COPD (Table 4). A greater number of patientsfliximab
mg/kg 5 mg/kg Combined
80 157
(15.6) 8 (10.0) 20 (12.7)
(6.5) 4 (5.0) 9 (5.7)
3 (3.8) 3 (1.9)
(9.1) 1 (1.3) 8 (5.1)
64 (0.67, 4.07) 1.11 (0.42, 2.96) 1.37 (0.60, 3.12)
91 (3.05, 10.32) 4.18 (1.80, 8.23) 5.07 (3.10, 7.83)
(9.1) 12 (15.0) 19 (12.1)
2 (2.5) 2 (1.3)
(5.2) 8 (10.0) 12 (7.6)
(3.9) 2 (2.5) 5 (3.2)
05 (0.37, 3.00) 1.83 (0.72, 4.66) 1.44 (0.60, 3.42)
lmonary disease (COPD).
Table 5 Summary of follow-up after first infusion: treated
patients with long-term safety follow-up information.
Placebo Infliximab
3 mg/kg 5 mg/kg Combined
Treated patients
with long-term
safety follow-up
information
35 35 37 72
Total patient-years
of follow-up
186 175 173 349
Primary study 29 27 31 59
RESULTSa COPD 76 73 68 141
Incidence of
malignancy
per patient year
0.04 0.05 0.04 0.04
Incidence of death
per patient year
0.03 0.04 0.06 0.05
a Remicade Safety Under Long-Term Study in chronic
obstructive pulmonary disease (COPD).
Infliximab long-term safety in COPD 429(n Z 12 [15.0%]) in the infliximab 5 mg/kg group died
compared with the infliximab 3 mg/kg and placebo groups
(nZ 7 [9.1%] each). This increase was driven largely by the
number of patients who died in the infliximab 5 mg/kg
group during the gap period (n Z 8) (Fig. 2). The distribu-
tion of deaths across all groups was similar when analyzed
according to age, sex, race, and COPD type at baseline
(data not shown). However, irrespective of treatment
group, a greater proportion of patients who smoked 50
pack-years versus <50 pack-years died (14.2% vs 7.0%,
respectively).
The hazard ratio for time to death for the 234 patients
treated in the phase 2 interventional study was 1.05 (95%
CI: 0.37, 3.00) for the infliximab 3 mg/kg group and 1.83
(95% CI: 0.72, 4.66) for the infliximab 5 mg/kg group versus
the placebo group. The incidence of deaths per patient-
year was greater in the infliximab 5 mg/kg group compared
with the placebo group and similar between the infliximab
3 mg/kg and placebo groups (Table 5). The cause of death
was consistent with the demographics and disease comor-
bidities present in this population of patients with COPD.
Discussion
The current report provides follow-up assessments for the
occurrence of cancer in patients with COPD who partici-
pated in the clinical assessment of infliximab. During the
44-week clinical trial of 234 patients, ten malignancies
were reported: one in the placebo group, five in the
infliximab 3 mg/kg group, and four in the infliximab 5 mg/
kg group. In the 17-month gap period between the studies,
there were six malignancies reported: three patients who
had been treated with placebo and three patients treated
with infliximab 5 mg/kg. Of the 107 patients who partici-
pated in the five-year long-term follow-up, an additional
nine malignancies were reported: five of 35 patients who
had been treated with placebo, three of 35 patients who
had been treated with infliximab 3 mg/kg, and two of 37
patients who had been treated with infliximab 5 mg/kg.
Thus, the difference in the number of malignanciesFigure 2 KaplaneMeier estimates of the cumulative inci-
dence of death in 234 treated patients in the phase 2 inter-
ventional study.observed in the initial study tended to equalize over time.
For the entire study period, the hazard ratio for the
development of malignancy in the two infliximab groups
was 1.37 (CI: 0.60e3.12). There was also a difference in the
number of deaths among the infliximab-treated patients
(hazard ratio 1.44 [CI: 0.60, 3.42]).
TNFa has been suggested to play a role in limiting cancer
pathogenesis. As a result, there has been concern that anti-
TNFa treatments may increase the risk of malignancy.27,28
Infliximab, which is indicated for several conditions,
including rheumatoid arthritis, Crohn’s disease, ankylosing
spondylitis, and psoriatic arthritis, has been carefully
monitored for the development of malignancy. Individual
clinical trials, which are generally of limited duration, have
reported varied results, in part due to small sample sizes.
As a result, meta-analyses have been performed to deter-
mine if the use of anti-TNFa treatments increases the risk
for malignancy. Bongartz et al. reported an odds ratio (OR)
of 3.3 (CI: 1.2e9.1) for malignancy in an analysis of nine
trials that included 5005 rheumatoid arthritis patients.27 A
more comprehensive meta-analysis was performed at the
behest of the European Medicines Agency29 and included 74
clinical trials and 22,904 patients. Data were assessed at an
individual patient level, which were available due to the
cooperation of all corporate sponsors. The analysis, which
was conducted by an independent academic group, used
several standardized definitions of incidence and prevalent
malignancy and included systematic case adjudication. This
analysis concluded that there was a 2.02 relative risk of
nonmelanoma skin cancer (CI: 1.11e3.95) and a relative
risk of 0.99 (CI: 0.61e1.68) for all other cancers. The
authors concluded that the data neither refuted nor veri-
fied a short-term risk for increased cancer with anti-TNFa
treatments.
Long-term assessment of cancer risk consequent to anti-
TNFa treatment has been performed in several observa-
tional studies. Wolfe and Michaud, using data from the US
National Data Bank for Rheumatic Diseases, reported an
increased risk for nonmelanoma skin cancer (OR: 1.5, CI:
430 S.I. Rennard et al.1.2e1.8) and possible melanoma (OR: 2.3, CI: 0.9e5.4), but
no observed increased risk for any other cancer (OR: 1.0,
CI: 0.8e1.2).30 Using linked databases in Sweden, Askling
reported no increased risk of cancer over a six-year follow-
up period in more than 6000 patients with rheumatoid
arthritis.31 In contrast, a prospective observational study,
reported by Mariette and colleagues, suggested an excess
of lymphomas among patients with rheumatoid arthritis
treated with anti-TNFa antibodies (standardized incidence
ratio 2.3, CI: 1.6e3.3.32 Diak et al. reviewed pediatric cases
of malignancies reported to the Food and Drug Adminis-
tration, which suggested the possibility of increased risk
from anti-TNFa treatment.33 However, differential report-
ing, the increased risk of malignancy associated with the
underlying conditions, and selection bias for treatment
initiation, confound any definite conclusions.
The current follow-up study was motivated because of
the marked difference in diagnosed cancers, nine among
157 infliximab-treated patients versus one among 77
placebo patients, in a prospective 44-week clinical trial
that included 24 weeks of active treatment and 20 weeks
of follow-up. Plans for the study began upon recognition
of the difference. Several of the participating centers
declined to participate in the follow-up, as did a number
of individual patients. As a result, the current follow-up
study includes only 107 of the original 234 patients. Two
other trials, which also evaluated the use of infliximab in
COPD, had been conducted but those centers declined to
participate in the current follow-up. The available data,
therefore, are limited. In addition, there was a gap period
between the completion of the initial trial and the
current follow-up. While available information is re-
ported, the lack of complete follow-up limits the inter-
pretation of malignancy and mortality rates.
Nevertheless, the differences in reported cancers were
much less marked with the additional follow-up data. Of
interest, the most prevalent cancer was lung cancer and
a heavier smoking history was associated with an
increased reporting of cancer, as would be expected.
The attenuation in the difference in cancers with follow-
up does not eliminate the possibility that infliximab could
contribute to the emergence of cancer. However, such an
effect was not observed in the meta-analyses of clinical
studies reported by Askling29 or by Bongartz.27 Wolfe
specifically assessed lung cancers in a US-based observa-
tional study and reported an odds ratio of 1.1 (CI: 0.7e1.8)
for 112 lung cancers observed among 8627 patients.30 All of
these studies included patients who differ in important
ways from the patients in the current trial. Many may have
been smokers, as smoking is a risk factor for rheumatoid
arthritis.34 Moreover, a number may have had COPD,
although this was not reported. However, smoking is
a major risk factor for lung cancer, and among smokers, the
presence of COPD increases the risk. Thus, the current
study population is likely at much greater risk for lung
cancer than the patients in previous analyses of cancer risk
following anti-TNFa therapy. It should be noted that the
continued smoking in patients with COPD has been associ-
ated with an increased risk of lung cancer and mortality
from lung cancer.8 In this and other studies, there was little
difference in risk in the first 5 years after cessation, but an
increased risk of lung cancer is present for up to 15 yearsafter smoking cessation. Although in the primary phase 2
interventional study, the incidence of “current smoking” at
the time of randomization was balanced among the 3
groups, there was an imbalance, with slightly lower
percentage of current smokers in the infliximab groups,
during the follow-up study. Despite this, there were
numerically more subjects with lung cancer in the two
infliximab groups. Whether infliximab might alter the risk of
emergent cigarette smoke-induced cancers, therefore,
cannot be resolved from the available data.
Anti-TNFa therapy has proven effective for several
chronic inflammatory conditions. There are a number of
mechanisms by which TNFa could contribute to the path-
ogenesis of COPD. The current study presents long-term
follow-up of patients with COPD who participated in
a phase 2 randomized clinical trial evaluating infliximab at
doses effective in rheumatoid arthritis. No clinical benefits
were observed in any of the primary or secondary
endpoints. It is possible, however, that TNFa may play
a role in a specific subset of COPD patients or at a specific
time in the course of the disease. For example, the
hypotheses that anti-TNFa therapy may have a therapeutic
benefit among patients with COPD who are cachectic or
who have very high levels of circulating TNFa remain
untested. The current report provides additional informa-
tion on the potential for adverse effects of infliximab. As
such, it can help inform the patient of the potential risks
that need to be assessed against any potential benefits.
Whether similar concerns would apply to other anti-
inflammatory treatments that may target mechanistic
pathways shared with TNFa is unknown, but should be
a concern leading to careful prospective monitoring.
In summary, the current study provides additional
observational information on a group of patients with COPD
who participated in a trial evaluating infliximab. The orig-
inally observed excess of malignancies in the infliximab-
treated groups was less prominent among those in whom
long-term follow-up was obtained. The excess malignancies
were most marked for lung cancers. Whether this repre-
sents an increase in emergent cancers during infliximab
treatment cannot be ascertained. The potential for anti-
TNFa treatment to contribute to cancer risk should be
considered in the design of future trials targeting TNFa and
related pathways for the treatment of COPD.
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